How to Get Zetia (Ezetimibe) in North Carolina

What Zetia (Ezetimibe) Does and Why Clinicians Prescribe It

Ezetimibe is a non-statin cholesterol-lowering agent that blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, reducing dietary and biliary cholesterol absorption by roughly 50%. As monotherapy it lowers LDL-C by 18 to 20%, and when added to a statin it contributes an additional 20 to 25% LDL-C reduction on top of the statin effect alone [1]. The drug is taken as a single 10 mg tablet once daily, with or without food, and does not require dose titration.

The FDA approved ezetimibe in October 2002 for primary hypercholesterolemia, mixed hyperlipidemia, and homozygous familial hypercholesterolemia [2]. The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol lists ezetimibe as a first-line non-statin agent for patients who cannot tolerate adequate statin doses or who need additional LDL-C lowering beyond what a statin alone provides [3]. The guideline states: "In patients with clinical ASCVD in whom LDL-C remains above 70 mg/dL on maximally tolerated statin therapy, it is reasonable to add ezetimibe" [3].

The landmark IMPROVE-IT trial (N=18,144) published in the New England Journal of Medicine demonstrated that adding ezetimibe 10 mg to simvastatin 40 mg reduced the composite endpoint of cardiovascular death, nonfatal MI, unstable angina, coronary revascularization, or nonfatal stroke by 6.4% relative risk reduction compared with simvastatin alone (32.7% vs. 34.7%, P<0.001) over a median 6-year follow-up [4]. That result confirmed the "lower is better" hypothesis for LDL-C and established ezetimibe as a proven cardiovascular risk-reduction agent, not just a lipid number mover.

Ezetimibe is generally well tolerated. Myopathy rates are not statistically distinguishable from placebo in published trials [4]. Common adverse effects include upper respiratory tract infection, diarrhea, and arthralgia, each occurring in fewer than 5% of patients [2].

Who Can Prescribe Zetia in North Carolina

Any licensed prescriber in North Carolina with Schedule II-VI DEA authority may prescribe ezetimibe, which is a non-controlled medication. That includes:

• Medical doctors (MD) and doctors of osteopathic medicine (DO) holding a full NC medical license.
• Nurse practitioners (NP) who hold prescriptive authority under a collaborative practice agreement or, since 2023, independently if they meet the state's autonomous practice criteria under NC General Statute 90-18.2 [5].
• Physician assistants (PA-C) practicing under a supervising physician agreement, as governed by the NC Medical Board [6].

Telehealth prescribers must also hold an active NC medical license or NC-specific telehealth authorization. North Carolina joined the Interstate Medical Licensure Compact, which means many out-of-state physicians hold NC compact licenses and can legally prescribe to NC residents via telehealth platforms [7].

A 2023 update to NC telehealth regulations removed the requirement for an in-person visit before a telehealth prescription can be issued for most non-controlled medications, including ezetimibe [5]. A synchronous video visit is sufficient to establish the prescriber-patient relationship, which matters if you prefer to avoid driving to a clinic.

How to Get a Zetia Prescription in North Carolina: Step by Step

Getting ezetimibe in North Carolina follows a straightforward clinical pathway. The steps below reflect both in-person and telehealth routes.

Step 1: Gather Your Lipid Panel Results

Most prescribers will want a recent fasting lipid panel (total cholesterol, LDL-C, HDL-C, non-HDL-C, triglycerides) before initiating ezetimibe. "Recent" typically means within the past 6 to 12 months, though some telehealth platforms accept results up to 24 months old if no major health changes have occurred. The AHA recommends a fasting state of at least 9 to 12 hours before the draw for the most accurate triglyceride and calculated LDL-C values [8].

If you do not have a current panel, many NC urgent care clinics, Quest Diagnostics locations, and LabCorp patient service centers offer direct-to-consumer lipid panels. Quest has more than 40 patient service locations across NC, and results typically return within 1 to 2 business days.

Step 2: Schedule an Appointment (Telehealth or In-Person)

Telehealth route. Several telehealth platforms licensed in North Carolina can evaluate and prescribe ezetimibe. A synchronous video or audio-visual appointment typically lasts 15 to 30 minutes. The clinician will review your lipid panel, cardiovascular risk factors, current medications, and any history of statin intolerance. If ezetimibe is appropriate, the prescription is sent electronically to your preferred NC pharmacy the same day, usually within a few hours of the visit.

In-person route. Your primary care physician, cardiologist, or endocrinologist can prescribe ezetimibe at a routine office visit. Patients already established with a provider simply need a medication review appointment, which is often available within a few days.

Step 3: Understand Prior Authorization if You Have Commercial Insurance

Prior authorization (PA) for brand-name Zetia is common among NC commercial health plans and both NC Medicaid programs (NC Medicaid Direct and NC Medicaid Managed Care). Plans typically require:

1. Documentation of an elevated LDL-C (most plans require LDL-C above 100 mg/dL, though thresholds vary).
2. Evidence of a statin trial at maximally tolerated dose, OR documented statin intolerance with at least two statins tried at different doses [9].
3. A diagnosis code consistent with primary hypercholesterolemia (ICD-10: E78.00) or mixed hyperlipidemia (E78.2).
4. For high-risk ASCVD patients, supporting clinical notes that LDL-C remains above the guideline target of 70 mg/dL on current therapy [3].

Generic ezetimibe (multiple manufacturers) is available without prior authorization at most NC pharmacies under most commercial plans, because the generic is on Tier 1 or Tier 2 of most formularies. If your plan requires PA only for brand Zetia, switching to the generic is the fastest workaround.

NC Medicaid covers ezetimibe for hyperlipidemia only in beneficiaries who also carry a type 2 diabetes diagnosis (ICD-10: E11.x). For all other hyperlipidemia indications, NC Medicaid does not cover the drug as of the 2025 formulary [10]. Patients in that situation should ask their provider about formulary alternatives or access the manufacturer's patient assistance program.

Step 4: Fill the Prescription at an NC Pharmacy

Generic ezetimibe 10 mg (30-count) lists for $10 to $20 at GoodRx cash-pay prices at major NC chains including CVS, Walgreens, Walmart Pharmacy, and Harris Teeter. The Merck patient assistance program, Merck Helps, covers brand Zetia at no cost for eligible uninsured patients earning below 600% of the federal poverty level. Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists generic ezetimibe at approximately $14 for a 90-day supply as of early 2025, with free shipping to NC addresses.

Most NC pharmacies dispense a 90-day supply at initial fill if the prescriber writes for it, which reduces per-unit cost and the number of refill trips.

Telehealth Access for Zetia in North Carolina

North Carolina has an active telehealth prescribing environment. The NC Medical Board's 2022 telemedicine policy clarified that a valid prescriber-patient relationship can be established via synchronous audio-visual technology for most chronic-disease medications, with no mandatory prior in-person encounter [5]. Ezetimibe qualifies under this policy.

The HealthRX clinical team uses a four-criterion framework when evaluating NC telehealth patients for ezetimibe:

1. Risk tier. The 2018 ACC/AHA pooled cohort equation 10-year ASCVD score guides whether ezetimibe is first-line (very high-risk patients with LDL-C above 70 mg/dL) or adjunctive (moderate-risk with LDL-C above 100 mg/dL after lifestyle changes).
2. Statin status. Is the patient on maximally tolerated statin therapy? Ezetimibe's clinical benefit is strongest on top of a statin, as IMPROVE-IT demonstrated [4].
3. Contraindication screen. Active liver disease and pregnancy (FDA Category C) are contraindications [2]. Bile acid sequestrants taken at the same time may reduce ezetimibe absorption by up to 55%; co-administration should be separated by at least 2 hours before or 4 hours after [2].
4. Lab currency. A lipid panel within 12 months is required; liver function tests (ALT, AST) are checked if the patient reports any hepatic symptoms or is starting a concurrent statin.

A synchronous video visit through HealthRX takes approximately 20 minutes for an established lipid management case. Prescriptions are routed electronically to the patient's preferred NC pharmacy or a mail-order pharmacy serving NC.

Labs Required Before Zetia in North Carolina

The minimum lab workup most NC clinicians request before starting ezetimibe is a fasting lipid panel [3] [8]. Liver function testing is not universally required before ezetimibe initiation the way it was historically required for statins, because ezetimibe carries no clinically significant hepatotoxic risk at therapeutic doses [2]. However, the ACC/AHA 2018 guideline recommends baseline ALT and AST if a statin is being started simultaneously, since separating statin-related from ezetimibe-related liver enzyme elevations later requires a baseline value [3].

Secondary causes of dyslipidemia, including hypothyroidism (TSH), nephrotic syndrome (urinalysis, creatinine), and uncontrolled diabetes (HbA1c), should be excluded before attributing elevated LDL-C solely to primary hypercholesterolemia [3]. Many NC telehealth providers will ask you to complete these labs at a local draw site before the prescribing visit if your records do not already include them.

Ongoing monitoring after starting ezetimibe consists of a repeat fasting lipid panel at 4 to 12 weeks after initiation to confirm LDL-C response, then annually if targets are met. The 2018 ACC/AHA guideline specifies the following LDL-C targets: below 70 mg/dL for very high-risk ASCVD patients, below 100 mg/dL for high-risk patients, and below 130 mg/dL for moderate-risk patients [3].

Transferring an Existing Zetia Prescription to North Carolina

If you are relocating to NC or moving pharmacies, transferring an ezetimibe prescription is straightforward. North Carolina follows the National Association of Boards of Pharmacy rules: a pharmacist at any NC-licensed pharmacy can contact the original out-of-state or in-state pharmacy to transfer the remaining refills, provided the original prescription has refills remaining and was issued less than one year ago (12-month shelf life for non-controlled prescriptions in NC) [11].

For electronic prescriptions originated in another state, the prescriber must be licensed to practice in NC (or hold an NC compact license) for the prescription to be valid in NC. If your prior prescriber is not NC-licensed, you will need a new prescription from an NC-licensed provider. A telehealth visit is the fastest way to accomplish this, often within 24 hours.

Mail-order prescriptions are fully transferable to an NC-licensed mail-order pharmacy as long as the prescriber holds an NC license or compact authorization.

503A Compounding Pharmacies and Ezetimibe in North Carolina

North Carolina has a strong network of 503A compounding pharmacies licensed by the NC Board of Pharmacy. A 503A pharmacy compounds medications for individual patient prescriptions, as opposed to 503B outsourcing facilities that produce bulk non-patient-specific batches [12].

Licensed NC 503A pharmacies may compound ezetimibe for an individual patient when a commercially available form does not meet the patient's clinical needs. Common reasons include:

• Swallowing difficulty. A compounded oral suspension or powder-in-capsule formulation for patients who cannot swallow the standard tablet.
• Dose customization. Very rarely, a clinician may request a non-standard dose (such as 5 mg) for a patient who experiences dose-dependent side effects at 10 mg.
• Combination formulas. Some compounding pharmacies prepare ezetimibe in combination with plant sterols or other lipid-active compounds, though evidence for these combinations is limited compared with the standalone drug studied in IMPROVE-IT [4].

The NC Board of Pharmacy maintains a public list of licensed 503A facilities at ncbop.org. Compounded ezetimibe is not FDA-approved as a finished dosage form; it is prepared under the prescriber's supervision for the specific patient [12]. Insurance rarely covers compounded versions when the commercially manufactured generic is available and clinically appropriate.

What Ezetimibe Costs in North Carolina

Cost is a common reason patients delay filling their prescription. Here is what NC residents can actually pay in 2025:

• Generic ezetimibe 10 mg, 30-count, GoodRx cash price: approximately $10 to $20 at most NC chain pharmacies.
• Generic ezetimibe 10 mg, 90-count, Cost Plus Drugs: approximately $14 with free shipping to NC.
• Brand Zetia 10 mg, 30-count, retail cash price: approximately $280 to $320 without insurance.
• Merck Helps program: brand Zetia at no cost for uninsured or underinsured patients meeting income criteria; apply at merckhelps.com.
• NC Health Insurance Marketplace plans: most Silver and Gold tier plans include generic ezetimibe on Tier 1 or Tier 2; typical copay is $0 to $15 per 30-day fill.

The cost difference between brand and generic is dramatic, and generic ezetimibe contains the same active ingredient at the same 10 mg dose. The FDA's bioequivalence standards require generic formulations to deliver 80% to 125% of the reference drug's bioavailability, and the approved generic ezetimibe products consistently fall within a much tighter range of 90% to 110% [13].

Ezetimibe and Cardiovascular Risk Reduction: The Evidence Base

Prescribing ezetimibe is not just about lowering a number on a lab report. The IMPROVE-IT trial, published in the New England Journal of Medicine in 2015 (N=18,144 post-ACS patients), demonstrated that every 1 mmol/L (38.7 mg/dL) reduction in LDL-C with ezetimibe plus simvastatin reduced major adverse cardiovascular events by approximately 6.4% compared with simvastatin alone [4]. The mean achieved LDL-C in the combination arm was 53.7 mg/dL vs. 69.5 mg/dL in the simvastatin-only arm, and that 16 mg/dL difference drove the outcome benefit over a median 6-year follow-up [4].

A 2022 meta-analysis published in JAMA Cardiology (N=176,000 patient-years across 14 trials) confirmed that ezetimibe reduces major vascular events in proportion to LDL-C lowering, consistent with the statin literature, with no evidence of harm at achieved LDL-C levels below 50 mg/dL [14]. The ACC/AHA's 2022 expert consensus on non-statin therapies reinforces ezetimibe as the preferred first add-on agent due to its safety profile, oral formulation, and decades of outcome data [15].

A Cochrane systematic review of ezetimibe monotherapy (12 randomized controlled trials, N=1,873) found a mean LDL-C reduction of 18.6% (95% CI: 15.7 to 21.6%) compared with placebo, with no statistically significant increase in serious adverse events [16]. This is the cleanest evidence for ezetimibe when used without a concurrent statin.

For patients with heterozygous familial hypercholesterolemia (HeFH), the combination of high-intensity statin plus ezetimibe is guideline-recommended as the starting regimen, not a step-up therapy [3]. HeFH affects approximately 1 in 250 people in the United States, meaning NC has an estimated 42,000 individuals with HeFH, most of them undiagnosed [17].

Statin Intolerance and Ezetimibe in North Carolina

Approximately 5 to 10% of patients on statin therapy discontinue due to muscle-related side effects, though the true rate of pharmacologically confirmed statin myopathy is closer to 0.1 to 0.5% [18]. Statin intolerance creates a clinical gap that ezetimibe can fill, because it achieves 18 to 20% LDL-C reduction through a completely different mechanism with no myopathic risk.

The GAUSS-3 trial (N=511) found that 43% of patients with self-reported statin intolerance could tolerate a rechallenge statin at a different dose or with a different statin, while 57% had confirmed intolerance on rechallenge [19]. For the 57% who truly cannot tolerate statins, ezetimibe becomes the primary LDL-C lowering agent, often combined with a PCSK9 inhibitor (evolocumab or alirocumab) for very high-risk patients who need greater than 20% additional reduction [15].

NC telehealth platforms can document statin intolerance history and generate the clinical notes needed for prior authorization of ezetimibe as a non-statin alternative, which is exactly the documentation most NC commercial plans require for PA approval [9].